Cargando…

Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway

Introduction: Nonalcoholic fatty liver disease (NAFLD) is a chronic disease characterized by fat deposits in liver cells, which can lead to hepatitis and fibrosis. This study attempted to explore the protective effect of vitamin D3 (VitD) against NAFLD. Methods: Adult male albino rats were randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Reda, Doha, Elshopakey, Gehad E., Albukhari, Talat A., Almehmadi, Samah J., Refaat, Bassem, Risha, Engy F., Mahgoub, Hebatallah A., El-Boshy, Mohamed E., Abdelhamid, Fatma M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228732/
https://www.ncbi.nlm.nih.gov/pubmed/37261280
http://dx.doi.org/10.3389/fphar.2023.1164512
_version_ 1785051034769424384
author Reda, Doha
Elshopakey, Gehad E.
Albukhari, Talat A.
Almehmadi, Samah J.
Refaat, Bassem
Risha, Engy F.
Mahgoub, Hebatallah A.
El-Boshy, Mohamed E.
Abdelhamid, Fatma M.
author_facet Reda, Doha
Elshopakey, Gehad E.
Albukhari, Talat A.
Almehmadi, Samah J.
Refaat, Bassem
Risha, Engy F.
Mahgoub, Hebatallah A.
El-Boshy, Mohamed E.
Abdelhamid, Fatma M.
author_sort Reda, Doha
collection PubMed
description Introduction: Nonalcoholic fatty liver disease (NAFLD) is a chronic disease characterized by fat deposits in liver cells, which can lead to hepatitis and fibrosis. This study attempted to explore the protective effect of vitamin D3 (VitD) against NAFLD. Methods: Adult male albino rats were randomized into four separate groups: the negative control group was fed a standard rat chow; the positive group received a high-fat diet (20%) and 25% fructose water (NAFLD); the VitD control group was intramuscularly treated with VitD (1,000 IU/kg BW) 3 days per week for 10 weeks; and the NAFLD group was treated with VitD therapy. Biochemical and hepatic histological analyses were performed. Hepatic oxidative stress and inflammatory conditions were also studied. Hepatic expression of sterol regulatory element-binding protein 1-c (SREBP-1-c), peroxisome proliferator-activated receptor alpha (PPAR-α), and insulin receptor substrate-2 was analyzed by quantitative real-time polymerase chain reaction. Results and discussion: The NAFLD rats exhibited elevated terminal body weight, hepatic injury markers, dyslipidemia, glucose intolerance, and insulin resistance. Moreover, the NAFLD rats had increased SREBP-1-c expression and reduced PPAR-α and IRS-2 expressions. Histological analysis showed hepatic steatosis and inflammation in the NAFLD group. In contrast, VitD administration improved the serum biochemical parameters and hepatic redox status in NAFLD rats. Also, VitD treatment ameliorated hepatic inflammation and steatosis in the NAFLD group by decreasing the expression of SREBP-1-c and increasing the expression of PPAR-α. Overall, these results suggest that VitD could have a protective effect against NAFLD and its associated complication.
format Online
Article
Text
id pubmed-10228732
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102287322023-05-31 Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway Reda, Doha Elshopakey, Gehad E. Albukhari, Talat A. Almehmadi, Samah J. Refaat, Bassem Risha, Engy F. Mahgoub, Hebatallah A. El-Boshy, Mohamed E. Abdelhamid, Fatma M. Front Pharmacol Pharmacology Introduction: Nonalcoholic fatty liver disease (NAFLD) is a chronic disease characterized by fat deposits in liver cells, which can lead to hepatitis and fibrosis. This study attempted to explore the protective effect of vitamin D3 (VitD) against NAFLD. Methods: Adult male albino rats were randomized into four separate groups: the negative control group was fed a standard rat chow; the positive group received a high-fat diet (20%) and 25% fructose water (NAFLD); the VitD control group was intramuscularly treated with VitD (1,000 IU/kg BW) 3 days per week for 10 weeks; and the NAFLD group was treated with VitD therapy. Biochemical and hepatic histological analyses were performed. Hepatic oxidative stress and inflammatory conditions were also studied. Hepatic expression of sterol regulatory element-binding protein 1-c (SREBP-1-c), peroxisome proliferator-activated receptor alpha (PPAR-α), and insulin receptor substrate-2 was analyzed by quantitative real-time polymerase chain reaction. Results and discussion: The NAFLD rats exhibited elevated terminal body weight, hepatic injury markers, dyslipidemia, glucose intolerance, and insulin resistance. Moreover, the NAFLD rats had increased SREBP-1-c expression and reduced PPAR-α and IRS-2 expressions. Histological analysis showed hepatic steatosis and inflammation in the NAFLD group. In contrast, VitD administration improved the serum biochemical parameters and hepatic redox status in NAFLD rats. Also, VitD treatment ameliorated hepatic inflammation and steatosis in the NAFLD group by decreasing the expression of SREBP-1-c and increasing the expression of PPAR-α. Overall, these results suggest that VitD could have a protective effect against NAFLD and its associated complication. Frontiers Media S.A. 2023-05-16 /pmc/articles/PMC10228732/ /pubmed/37261280 http://dx.doi.org/10.3389/fphar.2023.1164512 Text en Copyright © 2023 Reda, Elshopakey, Albukhari, Almehmadi, Refaat, Risha, Mahgoub, El-Boshy and Abdelhamid. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Reda, Doha
Elshopakey, Gehad E.
Albukhari, Talat A.
Almehmadi, Samah J.
Refaat, Bassem
Risha, Engy F.
Mahgoub, Hebatallah A.
El-Boshy, Mohamed E.
Abdelhamid, Fatma M.
Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title_full Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title_fullStr Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title_full_unstemmed Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title_short Vitamin D3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the SREBP-1-c/ PPARα-NF-κB/IR-S2 signaling pathway
title_sort vitamin d3 alleviates nonalcoholic fatty liver disease in rats by inhibiting hepatic oxidative stress and inflammation via the srebp-1-c/ pparα-nf-κb/ir-s2 signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228732/
https://www.ncbi.nlm.nih.gov/pubmed/37261280
http://dx.doi.org/10.3389/fphar.2023.1164512
work_keys_str_mv AT redadoha vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT elshopakeygehade vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT albukharitalata vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT almehmadisamahj vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT refaatbassem vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT rishaengyf vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT mahgoubhebatallaha vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT elboshymohamede vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway
AT abdelhamidfatmam vitamind3alleviatesnonalcoholicfattyliverdiseaseinratsbyinhibitinghepaticoxidativestressandinflammationviathesrebp1cpparanfkbirs2signalingpathway